HIMS
Hims & Hers Health, Inc.
SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE
Best Pharmaceutical Stocks 2026 →
Hims & Hers Health (HIMS) Stock: Buy, Sell, or Hold?
$20.81
+1.68 (+8.78%)
▲
5d:
-21.94%
30d:
-29.96%
90d:
-27.67%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 09, 2026
0d
Protect HIMS Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (88%)
Quality Score
46/100
Position
OVERSOLD
30-Day Fair Range
$24.68 – $30.27
Position: OVERSOLD
Forward P/E & Valuation
135.5x
STRETCHED
vs 49.5x historical avg
Wall Street Target
$28.85
+38.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$18.40 / $30.13
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: HIMS is down 21.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When HIMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: HIMS is currently trading at $20.81, which is considered oversold relative to its 30-day fair value range of $24.68 to $30.27. From a valuation perspective, the stock is trading at a premium (Forward PE: 135.5) compared to its historical average (49.5). At these levels, the market is pricing in 39.9% annual earnings growth.
Technical Outlook: Technically, HIMS is in a downtrend. Immediate support is located at $18.40, while resistance sits at $30.13. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $28.85 (+38.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HIMS is in a downtrend. Immediate support is located at $18.40, while resistance sits at $30.13. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $28.85 (+38.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$24.68 -
$30.27
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.6%
Trading Range & Key Levels
30-Day Trading Range
$24.68 -
$30.27
Current vs Trading Range
OVERSOLD
Support Level
$18.40
Resistance Level
$30.13
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding HIMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.8%)
- BULLISH: Trading 38.6% below Wall St target ($28.85)
- BULLISH: Expecting earnings turnaround to 39.9% growth with 48.6% revenue growth
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
135.48
Wall Street Target
$28.85
(+38.6%)
Revenue Growth (YoY)
48.6%
Earnings Growth (YoY)
-17.4%
Profit Margin
-6.7%
Valuation Premium vs History
+39.9% premium
PE vs Historical
135.5 vs 49.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+39.9%
(market-implied from PE analysis)
1-Year Target
$29.11
(+40%)
2-Year Target
$40.73
(+96%)
3-Year Target
$56.98
(+174%)
3-Yr Target (if PE normalizes)
(PE: 135→50)
PE COMPRESSION
$20.82
(0%)
Earnings growth offset by PE compression
Share HIMS Analysis
Share this live HIMS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (HIMS)
Bullish
15 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
14 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Investors expressed bullish sentiments towards $HIMS on StockTwits, despite missing earnings estimates and cutting EBITDA guidance in the latest Q3 report. The company is prioritizing a broader weight-loss offering and international expansion over immediate subscriber gains.
Key Retail Themes:
company's strategic focus on broader weight-loss offerings and international expansion
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 7:10 PM ET
Data refreshes hourly during market hours. Next update: 8:10 PM
Data refreshes hourly during market hours. Next update: 8:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HIMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
Advanced HIMS Option Strategies
Professional options setups generated by AI based on today's HIMS price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive HIMS Research Pages
